The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases
Open accessAbstract
There are limited data regarding the antifungal susceptibility of yeast causing vulvovaginal candidiasis, since cultures are rarely performed. Susceptibility testing was performed on vaginal yeast isolates collected from January 1998 to March 2001 from 429 patients with suspected vulvovaginal candidiasis. The charts of 84 patients with multiple positive cultures were reviewed. The 593 yeast isolates were Candida albicans ( n = 420), Candida glabrata ( n = 112), Candida parapsilosis ( n = 30), Candida krusei ( n = 12), Saccharomyces cerevisiae ( n = 9), Candida tropicalis ( n = 8), Candida lusitaniae ( n = 1), and Trichosporon sp. ( n = 1). Multiple species suggesting mixed infection were isolated from 27 cultures. Resistance to fluconazole and flucytosine was observed infrequently (3.7% and 3.0%); 16.2% of isolates were resistant to itraconazole (MIC ≥ 1 μg/ml). The four imidazoles (econazole, clotrimazole, miconazole, and ketoconazole) were active: 94.3 to 98.5% were susceptible at ≤1 μg/ml. Among different species, elevated fluconazole MICs (≥16 μg/ml) were only observed in C. glabrata (15.2% resistant [R], 51.8% susceptible-dose dependent [S-DD]), C. parapsilosis (3.3% S-DD), S. cerevisiae (11.1% S-DD), and C. krusei (50% S-DD, 41.7% R, considered intrinsically fluconazole resistant). Resistance to itraconazole was observed among C. glabrata (74.1%), C. krusei (58.3%), S. cerevisiae (55.6%), and C. parapsilosis (3.4%). Among 84 patients with recurrent episodes, non-albicans species were more common (42% versus 20%). A ≥4-fold rise in fluconazole MIC was observed in only one patient with C. parapsilosis . These results support the use of azoles for empirical therapy of uncomplicated candidal vulvovaginitis. Recurrent episodes are more often caused by non-albicans species, for which azole agents are less likely to be effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations
Sobel, J. D., Faro, S., Force, R. W., Foxman, B., Ledger, W. J., Nyirjesy, P. R., Reed, B. D., & Summers, P. R. (1998) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(98)80001-x · Cited by 694
Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033114 · Cited by 487
Has antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361 · cited 1×
“Previous studies correlating susceptibility test results of Candida species for azoles with clinical outcome support the “90-60 rule” established for bacterial infections: approximately 90% of infections due to susceptible isolates respond, while infections due to resistant isolates respond approximately 60% of the ti…”
ResultSelf-citationImmunopathogenesis of recurrent vulvovaginal candidiasis
Fidel, P. L., & Sobel, J. D. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.3.335 · Cited by 298
Pfaller, M. A., & Diekema, D. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3551-3557.2002 · Cited by 269 · cited 1×
“albicans bloodstream isolates is rare ( 1%) (16).”
BackgroundSelf-citationPfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., & Hajjeh, R. A. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00160-6 · Cited by 216
Self-citationTreatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine
Sobel, J. D., Chaim, W., Nagappan, V., & Leaman, D. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/s0002-9378(03)00726-9 · Cited by 207
Berg, A. O. (1984) · JAMA · doi:10.1001/jama.251.5.620 · Cited by 190
Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., & Hollis, R. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.4.1440-1446.2003 · Cited by 185
Self-citationPrevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women
Bauters, T. G. M., Dhont, M. A., Temmerman, M. I. L., & Nelis, H. J. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.125897 · Cited by 174
Treatment of Torulopsis glabrata Vaginitis: Retrospective Review of Boric Acid Therapy
Sobel, J. D., & Chaim, W. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.649 · Cited by 160
Chronic fungal vaginitis: The value of cultures
Nyirjesy, P., Seeney, S. M., GRODY, M. H. T., Jordan, C. A., & BUCKLEY, H. R. (1995) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(95)90347-x · Cited by 157
Vulvovaginal carriage of yeasts other than Candida albicans
Holland, J., Young, M. L., Lee, O., & Chen, S. C.-A. (2003) · Sexually Transmitted Infections · doi:10.1136/sti.79.3.249 · Cited by 143
Sobel, J. D., Zervos, M., Reed, B. D., Hooton, T. M., Soper, D. E., Nyirjesy, P., Heine, M. W., Willems, J., & Panzer, H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.1.34-38.2003 · Cited by 123
Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects and therapy
Sobel, J. D., Vazquez, J., Lynch, M., Meriwether, C., & Zervos, M. J. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/16.1.93 · Cited by 117 · cited 1×
“Most non-albicans Candida species have higher azole MICs, and infections they cause are often difficult to treat (10, 20, 21, 26).”
BackgroundPrevalence of and risk factors for fungal vaginitis caused by non-albicans species
Spinillo, A., Capuzzo, E., Gulminetti, R., Marone, P., Colonna, L., & Piazzi, G. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)80026-9 · Cited by 116
Vaginitis Due to Candida krusei: Epidemiology, Clinical Aspects, and Therapy
Singh, S., Sobel, J. D., Bhargava, P., Boikov, D. A., & Vazquez, J. A. (2002) · Clinical Infectious Diseases · doi:10.1086/343826 · Cited by 100
Over-the-counter and alternative medicines in the treatment of chronic vaginal symptoms
Nyirjesy, P., Weitz, M. V., GRODY, M. H. T., & Lorber, B. (1997) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(97)00242-1 · Cited by 95
Susceptibility profile of vaginal yeast isolates from Brazil
Ribeiro, M. A., Dietze, R., Paula, C. R., da Matta, D. A., & Colombo, A. L. (2001) · Mycopathologia · doi:10.1023/a:1010909504071 · Cited by 93
Carrillo‐Muñoz, A. J., Quindós, G., Tur‐Tur, C., Ruesga, M., Miranda, Y., del Valle, O., Cossum, P. A., & Wallace, T. L. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.3.397 · Cited by 83
Comparativein vitroactivity of antimycotic agents against pathogenic vaginal yeast isolates
Lynch, M. E., & Sobel, J. D. (1994) · Medical Mycology · doi:10.1080/02681219480000341 · Cited by 71
Mathema, B., Cross, E., Dun, E., Park, S., Bedell, J., Slade, B., Williams, M., Riley, L., Chaturvedi, V., & Perlin, D. S. (2001) · Clinical Infectious Diseases · doi:10.1086/322600 · Cited by 65
Blignaut, E., Messer, S. A., Hollis, R. J., & Pfaller, M. A. (2002) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00440-6 · Cited by 65
Self-citationSobel, J. D., & Vazquez, J. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.4.726 · Cited by 62
Arzeni, D., Poeta, M. D., Simonetti, O., Offidani, A. M., Lamura, L., Balducci, M. T., Cester, N., Giacometti, A., & Scalise, G. (1997) · European Journal of Epidemiology · doi:10.1023/a:1007366722235 · Cited by 31
The Incidence of Genitourinary Infections in a Cohort of Healthy Women
McCormack, W. M., Zinner, S. H., & McCormack, W. M. (1994) · Sexually Transmitted Diseases · doi:10.1097/00007435-199403000-00001 · Cited by 22
Prevalence of Vulvovaginal Candidiasis and Susceptibility to Fluconazole in Women
Bauters, T. G. M., Dhont, M. A., Temmerman, M., & Nelis, H. J. C. F. (2003) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200301000-00014 · Cited by 21
Dorrell, L. (2002) · Sexually Transmitted Infections · doi:10.1136/sti.78.4.308-a · Cited by 17
Cited by
Sobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900
“C. glabrata is also the most common NAC species found to be the causative agent in vulvovaginal candidiasis (VVC) (Corsello et al., 2003; Holland et al., 2003; Richter et al., 2005; Vermitsky et al., 2008; Mahmoudi Rad et al., 2012) and candiduria (Sobel et al., 2000; Kauffman, 2005).”
BackgroundCandida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
Candida Infections of the Genitourinary Tract
Achkar, J. M., & Fries, B. C. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00076-09 · Cited by 736
“32% versus 20 to 11%, respectively) (116, 184, 208, 249).”
BackgroundVulvovaginal candidiasis: Epidemiology, microbiology and risk factors
Gonçalves, B., Ferreira, C., Alves, C. T., Henriques, M., Azeredo, J., & Silva, S. (2016) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1091805 · Cited by 669
“In American (Richter et al., 2005), European (Corsello et al., 2003; Grigoriou et al., 2006; Paulitsch et al., 2006; Sojakova et al., 2004) and Australian (Holland et al., 2003) studies C. albicans was the most common specie identified in women with the disease (70.0–89.0%), followed by C. glabrata…”
BackgroundInfluential
Metadata
- Authors
- Richter, S. S., Galask, R. P., Messer, S. A., Hollis, R. J., Diekema, D. J., & Pfaller, M. A.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2005-05
- Volume
- 43
- Issue
- 5
- Pages
- 2155-2162
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2172046963
- Cited by
- 431
- References
- 29
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.